Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Drugs that lack single-agent activity: are they worth pursuing in combination?

Nature Reviews Clinical Oncology volume 14, pages 193–194 (2017)Cite this article

Subjects

Over the past decade, many anticancer drugs have been approved for use only in combination regimens and only in palliative settings, despite having negligible single-agent activity in the same disease. We examine whether these agents provide any tangible clinical benefits and are worthy of continued development, or whether R&D efforts would be better focused elsewhere.

...the clinical advancement of drugs in combination that lack single-agent activity should remain the exception, not the rule

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

References

  1. Zonder, J. A. et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood 120, 552–559 (2012).

    Article  CAS  Google Scholar 

  2. Wolf, J. L. et al. Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leuk. Lymphoma. 53, 1820–1823 (2012).

    Article  CAS  Google Scholar 

  3. Blackwell, K. L. et al. Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. Ann. Oncol. 20, 1026–1031 (2009).

    Article  CAS  Google Scholar 

  4. Ocaña, A., Amir, E., Vera, F., Eisenhauer, E. A. & Tannock, I. F. Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions. J. Clin. Oncol. 29, 254–256 (2011).

    Article  Google Scholar 

  5. Sledge, G. W. et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J. Clin. Oncol. 21, 588–592 (2003).

    Article  Google Scholar 

  6. Gyawali, B. & Prasad, V. Same data; different interpretations. J. Clin. Oncol. 34, 3729–3732 (2016).

    Article  CAS  Google Scholar 

  7. Inman, S. ODAC votes against panobinostat in multiple myeloma. OncLive http://www.onclive.com/web-exclusives/odac-votes-against-panobinostat-in-multiple-myeloma (2014).

    Google Scholar 

  8. Dimopoulos, M. et al. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Lancet Oncol. 14, 1129–1140 (2013).

    Article  CAS  Google Scholar 

  9. Orlowski, R. Z. et al. Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma. Cancer 122, 2050–2056 (2016).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haemato-Oncology, Nobel Hospital, Kathmandu, 21034, Sinamangal, Nepal

    Bishal Gyawali

  2. Division of Hematology Oncology, Knight Cancer Institute, Oregon Health and Sciences University (OHSU), 3181 South West Sam Jackson Park Road, Portland, 97239–3098, Oregon, USA

    Vinay Prasad

  3. Department of Public Health and Preventive Medicine, OSHU, 3181 South West Sam Jackson Park Road, Portland, 97239–3098, Oregon, USA

    Vinay Prasad

  4. Center for Ethics in Health Care, OHSU, 3181 South West Sam Jackson Park Road, Portland, 97239–3098, Oregon, USA

    Vinay Prasad

Authors
  1. Bishal Gyawali
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vinay Prasad
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vinay Prasad.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary information S1 (table)

Approvals of drugs with limited evidence of single-agent activity as combination therapies (DOC 53 kb)

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gyawali, B., Prasad, V. Drugs that lack single-agent activity: are they worth pursuing in combination?. Nat Rev Clin Oncol 14, 193–194 (2017). https://doi.org/10.1038/nrclinonc.2017.27

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2017.27

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research